Oculis Reports First Quarter 2025 Revenue

ZUG, Switzerland—Oculis Holding AG (Nasdaq: OCS / XICE: OCS), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases, has announced results for the first quarter ended March 31, 2025, and provided an overview of the company’s progress. The company reported a net loss of CHF 33.2 million, or $36.9 million, for the three months ended March 31, 2025, compared with CHF 16.1 million, or $18.4 million, for the same period in 2024. The company stated that the loss was primarily driven by advancements in clinical development programs, general and administrative expenses, and a CHF 8.8 million, or $9.8 million, increase in the non-cash fair value adjustment on warrant liabilities.